Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

OptiBiotix inks agreement to manufacture LPLDL in US market

The biotech firm said under the agreement, US Pharma Lab Inc (USPL) would be granted non-exclusive rights to manufacture and supply formulations containing the LPLDL strain
USA agreement
The agreement gives the firm access to the US$7.1bn US probiotic market

OptiBiotix Health plc (LON:OPTI) has signed a manufacturing and supply agreement with a US-based probiotic maker for its LPLDL probiotic strain.

The biotech firm said under the agreement, US Pharma Lab Inc (USPL) would be granted non-exclusive rights to manufacture and supply formulations containing the LPLDL strain.

READ: OptiBiotix Health unveils second distribution deal of the week for weight management product

USPL is a family owned business with facilities in the US, India, and China which focuses on the handling of challenging ingredients such as probiotics.

Opti said the agreement was “an important step” in its business to business (B2B) strategy of utilising its science with partner company expertise and market reach to create multiple products for consumers.

USPL’s pharmaceutical good manufacturing practice (GMP) certification for its probiotic manufacturing facility in New Jersey also offered the possibility of utilising LPLDL in pharmaceutical applications, Opti said.

The agreement gives the firm strategic access to the US probiotic market, the world’s largest with an estimated retail value of US$7.1bn.

Per Rehne, chief commercial director of OptiBiotix, said that the agreement extended the firm’s product offering for LPLDL and had created access to the US market with “an established industry supplier”.

He added that the company would showcase the first formulation from the agreement at the Supply Side West ingredients conference in November.

The agreement follows the second distribution agreement signed for OptiBiotix’s SlimBiome weight management product with South African firm Formulation Creations last week.

In a note to clients, analysts at City broker finnCap said the deal demonstrated the company's ability to "attract high calibre, global partners, eager to utilise the potential inherent within LPLDL".

--Adds broker comment--

OptiBiotix Health plc

Loading charts
Loading charts
View full OPTI profile View Profile

OptiBiotix Health plc Timeline

Related Articles

Widecells
September 27 2018
WideCells has undertaken a review of the business to deliver a strategy that will generate revenue, reduce overheads and achieve profitability
scientist looking through microscope
April 11 2018
Kumaraguru Raja sees “multiple catalysts” in the year ahead which could put a rocket under the share price
1528305384_Untitled-design-(3).jpg
June 06 2018
Ventripoint received key FDA approval to sell the device with the four-chamber heart analysis last month

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use